MétaCan
Menu
Back to cohort
Record W4213442897 · doi:10.1017/s1092852922000128

Early optimized pharmacological treatment in patients with depression and chronic pain

2022· review· en· W4213442897 on OpenAlexafffundabout
Oloruntoba Oluboka, Martin A. Katzman, Jeffrey Habert, Atul Khullar, Margaret Oakander, Diane McIntosh, Roger S. McIntyre, Cláudio N. Soares, Raymond W. Lam, Larry J. Klassen, Robert L. Tanguay

Bibliographic record

VenueCNS Spectrums · 2022
Typereview
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsQueen's UniversityTelus (Canada)Lakehead UniversitySTART ClinicUniversity of TorontoUniversity of British ColumbiaNOSM UniversityMental Health Research CanadaUniversity of Calgary
FundersCanadian Institutes of Health ResearchHealth CanadaSt. Jude MedicalBausch HealthMovember FoundationSunovionH. Lundbeck A/SServierNovo NordiskAllerganEli Lilly and CompanyCanadian Network for Mood and Anxiety TreatmentsUniversity Health Network FoundationAmgenLakehead UniversityPfizer CanadaMitacsBC Children's HospitalUniversity of OttawaGovernment of AlbertaIndiviorSanofiPfizerAlberta InnovatesEisaiPurdue University
KeywordsChronic painDepression (economics)MedicineMajor depressive disorderComorbidityAntidepressantAnxietyMoodPsychiatryMood disordersPharmacotherapyPhysical therapy

Abstract

fetched live from OpenAlex

Abstract Major depressive disorder (MDD) is the leading cause of disability worldwide. Patients with MDD have high rates of comorbidity with mental and physical conditions, one of which is chronic pain. Chronic pain conditions themselves are also associated with significant disability, and the large number of patients with MDD who have chronic pain drives high levels of disability and compounds healthcare burden. The management of depression in patients who also have chronic pain can be particularly challenging due to underlying mechanisms that are common to both conditions, and because many patients with these conditions are already taking multiple medications. For these reasons, healthcare providers may be reluctant to treat such patients. The Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines provide evidence-based recommendations for the management of MDD and comorbid psychiatric and medical conditions such as anxiety, substance use disorder, and cardiovascular disease; however, comorbid chronic pain is not addressed. In this article, we provide an overview of the pathophysiological and clinical overlap between depression and chronic pain and review evidence-based pharmacological recommendations in current treatment guidelines for MDD and for chronic pain. Based on clinical experience with MDD patients with comorbid pain, we recommend rapidly and aggressively treating depression according to CANMAT treatment guidelines, using antidepressant medications with analgesic properties, while addressing pain with first-line pharmacotherapy as treatment for depression is optimized. We review options for treating pain symptoms that remain after response to antidepressant treatment is achieved.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.005
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.314
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2022
Admission routes3
Has abstractyes

Explore more

Same venueCNS SpectrumsSame topicTreatment of Major DepressionFrench-language works237,207